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Cystic echinococcosis (CE) is an important helminthic zoonotic disease caused by theEchinococcus granulosus complex. In humans,
CE is a chronic disease driven by the growth of echinococcal cysts in different organs. Prognosis of this disease depends onmultiple
factors, including location, number, size, and stage of the cysts, making CE a disease of complex management. CE is usually
asymptomatic for years and attracts limited attention from funding organizations and health authorities. For this reason, only
experts’ recommendations are available but no evidence-based conclusions have been drawn for CE clinical management. One of
those pitfalls refers to the lack of evidence to support the use of serological tools for the diagnosis and follow-up of CE patients.
In this respect, crude antigens are used to detect specific antibodies in patients, giving rise to false positive results. The advent of
molecular techniques allowing the production of recombinant proteins has provided a number of candidate antigens that could
overcome the problems associated with the use of crude parasite extracts in the serological assays. In this review, we present the
last advances in this field, proposing the use of serology to support cyst stage-specific diagnosis and follow-up.
1. Introduction
Cystic echinococcosis (CE) is a parasitic disease caused by
the larval stage (metacestode) of Echinococcus granulosus
complex which affects livestock, wildlife, and humans. CE
has a worldwide geographic distribution, remaining highly
endemic in many pastoral communities, including several
European countries [1]. CE global prevalence is estimated
at 2-3 million human cases and a burden of 1 million
DALYs accounting for underreporting [2]. In humans, CE
is a chronic disease characterized by the long term growth
of hydatid cysts in internal organs, mainly liver and lungs,
with a complex clinical management. CE results in severe and
life-threatening complications, with estimatedmortality rates
of 2–4% per 100.000 inhabitants [3, 4]. Many CE cases are
asymptomatic for years and its diagnosis is still challenging
due to the absence of pathognomonic signs. For this reason
CE is frequently underdiagnosed and detected only when
complications arise or by chance. Additionally, the clinical
management of CE (i.e., surgery, percutaneous treatment,
and/or chemotherapy) has many associated risks for relapses,
pointing out the importance of the follow-up of patients.
CE diagnosis and monitoring firstly rely on imaging
techniques. Ultrasonography (US) standardized classification
of stage-specific cystic images has been issued by the WHO
Informal Working Group on Echinococcosis (WHO-IWGE)
for the diagnosis and the clinical management of CE [5].
Effective serological tests for CE diagnosis would be of great
help to define and support cyst status and their evolution
(active: CE1, CE2, and CE3b, transitional: CE3a, or inac-
tive: CE4 and CE5) [5, 6]. The main serological methods
used for human CE diagnosis and follow-up are based on
the detection of specific IgG antibodies. In this context, a
number of drawbacks have been detected, including low
sensitivity/specificity (Se/Sp) and a poor prognostic value for
follow-up due to the long-lasting persistence of antibodies
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against hydatid fluid (HF) [7].These pitfalls lead clinicians to
consider serology against HF as an approach of little value,
with doubtful benefit for the clinical management of CE.
Alternativemethods based on the detection of other antibody
isotypes and IgG subisotypes against HF have been published
[8]. Additionally, many authors have focused their research
both on recombinant proteins and on synthetic peptides, to
develop more sensitive and specific tests. Numerous recom-
binant proteins (Rec) and related peptides, mainly derived
from the antigen B and antigen 5, have been tested for the
detection and follow-up of antibodies in correlation with US
findings. Unfortunately, available data were generated from
small and underpowered clinical studies that have showed
dissimilar Se and Sp for the same recombinant antigen [9].
Nevertheless, there are hints showing that some antigens
are differentially expressed in different cyst stages, and thus
antibody levels against these antigens could be associated
with cyst activity and posttreatment outcome (i.e., surgery
or chemotherapy) and could be applied for diagnosis and
follow-up of CE patients [9, 10]. In this context, a better
characterization and standardization of each antigen should
be performed to clearly define its role within CE serology.
In this paper we summarize the current knowledge on
the use of HF for human CE diagnosis. Additionally, results
obtained from different purified fractions of parasite anti-
gens, recombinant antigens, and synthetic peptides are also
revised. A comprehensive review of the different available
antigens and their performance in the diagnosis of CE was
published by Carmena and colleagues [11]. In this review, we
also update the findings about the available serological tools
from 2006 to date.
2. Hydatid Fluid
HF is a complex mixture of parasite-derived proteins, mainly
produced by the germinal layer of the cyst. Some of the
HF components have been characterized as highly immuno-
genic, reaching the host environment and triggering antibody
responses. The HF is the main antigenic component in the
majority of commercially and in-house serological assays.
This antigen mixture is used in several techniques such as the
enzyme linked immunosorbent assay (ELISA), the indirect
haemagglutination test (IHA), and the immunoblotting (IB).
Both the ELISA and the IHA are usually the first line tests
for CE patients, while the IB is used as confirmatory test. As
mentioned, the use of HF for the detection of CE specific
antibodies is limited by several drawbacks. First, a percentage
of CEpatients are serological negative againstHF. Specifically,
the use of HF for the detection of total IgG in ELISA test
leads to variable results regarding Se and Sp. In Table 1, a
number of recent studies that used IgG-ELISA tests for CE
diagnosis are shown. Se reported in these studies varied from
64.8% to 100%. Reasons for false negative results depend
on several factors comprising cyst location other than the
liver [12, 13], early (CE1) and inactive (CE4 and CE5) cyst
stages [14–16], serum collection before treatment [15, 17],
single and small cysts [17], andHF antigenic source variability
[18]. Additionally, E. granulosus complex comprises several
genotypes that potentially express different antigenic sets. For
instance, it has been shown that the G1 and G2 genotypes
from Europe, contrary to those from China, express high
quantities of antigen B2 in HF [19].This may lead to different
diagnostic performance of a specific HF. The differential
expression of antigens is not only a qualitativematter, but also
quantitative, depending on cyst stages. Recently, a proteomic
and immunoproteomic study has shown that CE1 and CE2
cyst stages differ in the expression of their immunodominant
antigens (antigen B and antigen 5). Antigen 5 is predominant
and recognized by antibodies from patients with early cyst
stages, while antigen B is the most scarce in CE1 cyst stage
andmainly detected in patients with CE2 and CE3 cyst stages
[20]. These differences might be useful in clinical practice
to correctly define cyst stages and their viability by using
the most indicated antigen for a stage-specific diagnosis. A
second problem using HF is the percentage of false positive
results detected. For instance, IgG-ELISA tests based onHFas
antigen give rise to low false positive results in healthy donors
(e.g., Sp from 87.5% in Indian donors to 100% in Italian
donors) [15, 21]. Cross-reactivity is quite high in patients with
other parasitic diseases, such as alveolar echinococcosis (AE)
and cysticercosis, but also schistosomiasis and fascioliasis
[22, 23]. For instance, the cross-reactivity of E. granulosusHF
with antibodies from AE patients can reach more than 50%
[17]. The HF has also been shown not to be a good antigen
for patients’ follow-up during the clinical management of CE.
During the follow-up, ELISA-IgG test is difficult to interpret
[24], and anti-HF IgG antibody reactivity may remain high
many years after successful cyst removal [25].
The detection of antibodies other than IgG has shown
some promising results in relation to cyst activity, relapses,
and follow-up. It has been shown that both IgG2 and IgG4
could be related to cyst stages, disease evolution, and relapses
[9, 26, 27]. Remarkably, it is known that the subisotype
responses against CE1, CE2, and CE3 cyst stages are mainly
IgG4, while IgG1, IgG2, and IgG3 responses predominate
against CE4 and CE5 cysts, although this is still a question
of debate [11, 22]. Antibody isotypes different than IgG can
be also detected against HF in CE patients. IgE and IgM
antibodies have been considered as better markers than IgG
after chemotherapy and surgery [28]. Nevertheless, these
isotypes are more frequently underdetected in CE patients,
similar to different IgG subisotypes [29–31].
3. Antigens Derived from Hydatid Fluid
3.1. Antigen B. In an attempt to overcome the problems
related to the use of HF for the detection of antibodies in CE
patients,many authors have described the production and the
use in serological tests of partially purified native antigens,
recombinant antigens, and synthetic peptides. These are
mainly represented by the two most immunogenic antigens
in HF: antigen B (EgAgB) and antigen 5 (EgAg5).
EgAgB is a polymeric protein of 120–160 kDa that dis-
sociates under reducing conditions in 8, 16, and 20–24 kDa
subunits. Its biological role includes the protease inhibitor
activity, neutrophil chemotaxis inhibition, triggering of non-
protective Th2 responses, induction of apoptosis of immune
cells, and sequestration of xenobiotics [22]. EgAgB is codified
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Table 1: Performance of the hydatid cyst fluid in ELISA test for the detection of total IgG in CE patients (articles published from 2006).
Number of CE patients Confirmatory test Sensitivity (%) Negative serology more frequent when Reference
23 Histopathology 100 Not specified
[40]5 Imaging techniques plus serology 80 Not specified
13 Serology 100 Not specified
41 Surgery 95.1 Not specified [21]
6 Imaging techniques 66.7 Cyst location other than liver [12]
144 Imaging techniques 92.4 CE1, CE4, and CE5 cyst stages [14]
123 Imaging techniques 64.8∗ CE4 and CE5 cyst stages, no pretreatment [15]
59 Surgery 95.1 Not specified [20]
10 Surgery 100 Not specified [52]
54 Surgery 81.5 Single cyst, no pretreatment [17]186 Surgery 83.3
32 Imaging techniques 93.8 CE4 and CE5 cyst stages [16]
155 Surgery 90.3∗ Not specified [29]
40 Surgery 92.5 Not specified [30]
47 Surgery
95.71
HF collected from cysts of different hosts
or of different anatomical locations from
the same host
[18]
93.62
91.43
97.84
93.65
78.56
72.27
63 Surgery 90.5 Not specified [48]
82.4∗
68 Imaging techniques 92.6 Lung cysts [13]
∗Commercial test; HF of cysts from 1sheep liver, 2sheep lungs, 3goat liver, 4human liver, 5camel lungs, 6cow lungs, and 7cocktail.
by a multigenic family, with at least five genetic groups:
EgAgB1, EgAgB2, EgAgB3, EgAgB4, and EgAgB5 [32–35].
These different subunits share from 44% to 81% of sequence
identity. Each isoform has more than 90% homology with
Echinococcus granulosus and E. multilocularis species, and
although lower, similar antigens are also found in the genus
Taenia [11].These homologies can give rise to cross-reactivity
with other helminthic parasites. EgAgB has been obtained
as a native purified antigen, in its recombinant form. The
purified native protein has a Se ranging from 60% to 85%
in ELISA test and from 60% to 92% in immunoblot [11].
From 2006 up to date, several publications showed a high
variability in the Se of this purified antigen, ranging from
54% to 100% (Table 2). Different cyst stages and their follow-
up in US may reflect different profiles of antigens produced
and released by the host immune system [20]. For instance,
EgAgB recombinant antigen, in ELISA test, showed a Se
of 74%, 96%, 90%, and 56% in patients with CE1, CE2,
CE3, and CE4/CE5 cyst stages, respectively [36]. Additional
reasons for false negative results have been pointed out
by several authors, including cyst localization other than
liver and small size of cysts (see Table 2). These results are
similar to those found for false negative reactions against
HF. The heterogeneity and thus the limited value of native
antigens are also found when the purified EgAgB is used for
the serodiagnosis of CE patients. In this respect, antigens
purified from different sources of HF result in a variable Se in
the same patients’ cohort (from 82.1% to 96.9%; [37]; Table 2).
In its recombinant form (Rec), mainly two isoforms have
been assayed: RecEgAgB1 and RecEgAgB2. RecEgAgB1 gives
rise to variable sensitivities, ranging from 55% to 84% [11]
and from 71% to 94.6% in subsequent studies [38] (Table 2).
The lowest Se (71%; [38]) was attributed to false negative
results due to patients with Echinococcus genotypes other
than G1. Nevertheless, additional factors such as the presence
of CE4 and CE5 cyst stages and serum sampling collection
with respect to treatment are probably contributing to false
negative results against this recombinant antigen [15]. Some
of these factors have been also pointed out for RecEgAgB2,
for which false negatives have been related to single cysts
and to sera collected before treatment with benzimidazoles
[17]. RecEgAgB2 has given rise to very variable sensitivities
as well ([11]; Table 2). A modified version of the RecEgAgB2,
consisting of twofold tandem repeat of the original recom-
binant protein, showed a Se similar to the single antigen
unit [17]. Additional isoforms of EgAgB have been tested on
few occasions (Table 2). RecEgAgB3 and B5 did not improve
the Se of other antigenic isoforms [19], but RecEgAgB4 has
shown promising results (Se from 75.8% to 91.7%) [19, 39].
Remarkably, EgAgB3 andB5were not found after a proteomic
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study on the composition of the HF in CE1 and CE2 cyst
stages from sheep [40].
As mentioned, several synthetic peptides derived from
EgAgB1 have been also tested in ELISA for the detection
of specific antibodies. From those tests, the most promising
results have been obtained with the p176 peptide ([11];
Table 2). Nevertheless, the diagnostic performance of syn-
thetic peptides has been worse than that of the whole original
molecule, either in its purified native or in recombinant
forms. In addition, pooling three peptides has not resulted
in the improvement of the test Se [41]. In any case, the use
of bioinformatics for peptides selection and their screening
in high-throughput platforms have been stated as a proof
of principle and this approach could be used in the future
for the identification of relevant diagnostic epitopes. As
mentioned, a dominant IgG4 response is usually associated
with active and transitional cysts, whereas inactive cysts
mainly trigger IgG1, IgG2, and IgG3 responses. This has
important implications in the interpretation of the usefulness
of the detection of different IgG isotypes, since the level of
reactivity of each subisotype could be driven by the cyst stages
found in patients. This is the case for IgG4, since the Se
obtained when detecting this subisotype is lower than that
detected when total specific IgG levels are evaluated [42].
Whether this lower Se is associated with inactive cysts, it
should be further evaluated to ascertain the usefulness of
IgG4 instead of total IgG, both for the diagnosis and for the
follow-up of CE patients. The Sp of EgAgB in its different
isoforms is also variable, although the main cross-reactivity
has been reported with patients affected by AE and cysticer-
cosis [11]. Additionally, antibodies from patients with other
parasitic diseases including onchocerciasis, schistosomiasis,
and toxocariasis have given rise to false positive reactions
when tested against EgAgB [11]. It is worth mentioning the
efforts of several authors to test new affordable and easy to
use serological techniques instead of ELISA or the IB tests,
making those immunoassays stand out based on particles
such as DIGFA (dot immunogold filtration assay [43, 44];
Table 2).
In the light of the results obtained by several authors
using EgAgB, this antigenic family looks promising for the
serodiagnosis of CE patients and potentially useful in the
follow-up. Anyway, testing of this antigen family obtained in
a standardized format, with a well-defined and wide panel
of CE samples, including the clinical information influencing
the interpretation of the test (the parasite genotype, location,
number, size, and type of cysts, and presence of complications
and coinfections), should be further performed.
3.2. Antigen 5. Antigen 5 (EgAg5) is also an abundant highly
immunogenic component of HF. EgAg5 is a thermolabile
protein of around 400 kDa, composed of two subunits of
57 and 67 kDa. Studies on the N-terminal sequence of
the 38 kDa subunit have shown that several isoforms exist
similar to EgAgB, and thus EgAg5 could be also coded by
a multigenic family [45]. The biological function of EgAg5
is largely unknown, and although the 38 kDa subunit shows
homologies with trypsin peptidases, the enzymatic activity
is lacking [46]. Additionally, the smallest subunit of 22 kDa
contains proteoglycans of the heparan sulfate group and
calcium-binding motifs, suggesting that this subunit could
interact with the extracellularmatrix and the cell surface [47].
Molecules very similar to EgAg5 (more than 90% iden-
tity) are also expressed by E. multilocularis and the genus
Taenia; thus cross-reactivity of this antigen with antibodies
from patients affected by AE and cysticercosis is expected.
As we explain in the following paragraphs, the diagnostic use
of EgAg5 has shown mainly drawbacks regarding Se and Sp.
The purified native EgAg5 has been obtained using different
methodologies, including size exclusion chromatography and
immunoaffinity. Lately, an easy and efficient method for the
enrichment of this antigen from HF has been described
[48]. Variability of its performance in serodiagnosis could
be also attributed to differences in the clinical status of the
patients. For instance, EgAg5 seems to play a role in the
induction of specific antibodies mainly when CE1 and CE5
cyst stages are present [40].This variable Se has been reported
by several authors, ranging from 50% to 87.5% [11, 49]. As
recombinant proteins, EgAg5 has been tested in its full format
(RecEgAg5) and in its 38 kDa version (RecEgAg53.38) by
Auer and colleagues [50]. Although the 38 kDa subunit has
been described as the most antigenic component detected
by IB, the Se of the corresponding recombinant antigen
was very low (21%) [50, 51]. Similarly, low and variable
sensitivities (from 16% to 85%) have been detected using the
p89-122 EgAg5 peptide [11]. Due to the low Se of EgAg5 and
derivatives, this antigen has been less frequently tested than
EgAgB. Nevertheless, reasons for this low Se could be due to
cyst stage; thus the usefulness of this antigen for the detection
of early active and late inactive cyst lesions should be further
evaluated.
3.3. Other Antigens. The most frequently used crude extract
of E. granulosus for the serodiagnosis of CE has been the
somatic extract of protoscoleces (EgPpsSom).This extract has
a Se ranging from 69.4% to 96.9% [11, 16, 43, 44, 52–54].
When compared with HF, the EgPpsSom performs worse.
Less frequently, other somatic extracts have been applied in
the serodiagnosis of CE patients such as those derived from
the cyst wall (96.7% Se; [52]), the tegument of protoscoleces
(81.3% Se; [16]), and the adult worm (82% Se; [55]). Cross-
reactivity of those extracts is similar to that detected in
HF. Drawbacks associated with the heterogeneity of somatic
extracts could be attributed to these antigenic preparations.
In addition, reasons for the presence of false negative results
are similar to those found when the HF is used as antigenic
source (cyst location other than liver, small size cysts, and
CE1, CE4, and CE5 cyst stages).
Additionally, several recombinant antigens different from
EgAgB and EgAg5 have been obtained by several authors and
tested for the diagnosis of CE. These include, among others,
the malate dehydrogenase (RecEgMDH), the calcium bind-
ing protein (RecEgCaBP), the actin filament fragmenting
protein (RecEgAFFP), the RecEgEpC1, the thioredoxin per-
oxidase (RecEGTPx), and the RecEg19 [11, 56, 57]. RecEGTPx
and RecEg19 showed low Se (<45%; [56–58]). The rest of
the above-mentioned antigens showed variable Se (even for
the same recombinant) ranging from 45% (MDH) to 90%
6 BioMed Research International
(MDH, EpC1) and variable Sp (even for the same antigen)
ranging from 83% to 95% [11]. For this reason these antigens
could be considered as good alternatives for serological tests,
although further characterization is needed to evaluate their
diagnostic potential.
4. Antigens for Clinical Management
The clinical management of CE should be based on rec-
ommendations done by experts and driven by cystic stages
identification [54]. In this context, the WHO-IWGE has
proposed a cyst classification based on active, transitional,
and inactive cysts.
Some antigens could be mainly expressed by defined
cyst stages, showing that serology could be potentially useful
for the definition of cyst activity and thus for the clinical
management of CE patients. As mentioned, the HF has been
also evaluated for the follow-up of patients treated by surgery
and/or chemotherapy, but its usefulness is hampered by the
long persistence of antibodies in patients with nonactive
cysts [59]. A better correlation of specific antibodies against
defined active cyst stages has been reported in patients after
surgical treatment, including EgAgB [59, 60], EgAgP29 [60],
and the heat-shock protein 20 [61]. Several authors have also
found a correlation between a low level of specific antibodies
against RecEgAgB2, RecEgAgHSP20, and RecEgAgB1 and
the presence of inactive cysts [36, 59, 61]. Nevertheless, some
of those antigens are not recognized by a percentage of
CE patients [60]. Additionally, it has been shown that the
banding pattern in IB from CE patients changes depending
on the cyst stage [62].
Similarly, other authors have detected the loss of defined
bands in IB after cure.The identification and characterization
of the above-mentioned antigens could support the clini-
cal decision making actually based on imaging techniques.
Similarly, the shift of defined subisotypes of IgG antibodies
during cyst evolution could be used for the follow-up of CE
patients. As mentioned, IgG4 levels could be correlated with
cyst activity, and declining of the levels of isotypes other than
IgG seems to be useful to define the success of treatment
[26, 27]. Nevertheless, detectable levels of specific IgG4 and
especially of IgE and IgM are only found in a relative small
percentage of CE patients.
5. Conclusions: A New Hope for the Future?
Diagnosis and follow-up of CE patients are mainly based on
imaging techniques. These can be used for the identification
of cystic stages, leading to a stage-specific approach in CE
clinical management. Serological tools supporting imaging
techniqueswould be desirable.However the available tests are
based on antibodies against crude antigens and thus marred
by poor Sp and Se, with low or no usefulness for the follow-
up of patients during the treatment. Specific recombinant
antigens have good potential as diagnostic and follow-up
tools for CE, but progress in this field is hampered by lack
of standardization. Thus, a challenge still exists to develop a
reliable world standard based on serology for the diagnosis
and monitoring of CE patients. In this respect, a multicentre
study with a wide panel of sera from CE patients, including
relevant clinical data to properly define the usefulness of the
available recombinant antigens, should be performed. Along
this path, a project focusing on CE has been recently funded
by the European commission under the Seventh Framework
Programme (HERACLES; http://www.heracles-fp7.eu/). In
the framework of HERACLES, six recombinant antigens
(RecEgAgB1, RecEgAgB2, RecEgAg5, RecEgAgMDH,
RecEgAgCaBP, and RecEgAgAFFP) will be tested for the
serodiagnosis and follow-up of CE on a wide panel of
samples obtained from extended ultrasound surveys in
Eastern Europe. These recombinant antigens have been
already produced in a standardized way and preliminary
tested in ELISA for the detection of specific IgG in sera.
Additionally, two databases for the collection of clinical
data from retrospective/prospective patients providing
serum samples have been developed (the database behind
the European Register of Cystic Echinococcosis ERCE,
http://www.heracles-fp7.eu/erce.html, and CYSTRACK
database, http://cystrack.irnasa.csic.es). Hosting of samples
and clinical data has been organized in a dedicated biobank
(EchinoBiobank). This strategy will hopefully pave the way
to improve the diagnosis and follow-up of CE patients,
providing evidence-based data on the usefulness of serology
in CE clinical management.
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